Every day, your cells send out tiny membrane-wrapped parcels called extracellular vesicles, or EVs. Very normal. Very efficient. A bit like biological courier service, except instead of socks or a replacement phone charger, the cargo can be proteins, RNA, lipids, and assorted molecular gossip. The new review by Cai and colleagues argues that in solid tumors, these little parcels are not side noise - they are part of the operating system.[1]
That matters because cancer is not just a pile of rebellious cells growing too fast. It is a whole badly managed network. Tumor cells talk to immune cells, stromal cells, blood vessels, and even distant organs. EVs help route those messages. Sometimes they tell nearby cells to support growth. Sometimes they help prepare future metastatic sites like a questionable facilities team setting up a second office before anyone approved the lease.
Tiny bubbles, suspiciously busy
EVs are small particles released by cells. They are enclosed by a lipid membrane and carry bits of the parent cell's internal state. Think of them as encrypted status packets from one node to another. In healthy tissue, that kind of communication helps coordinate repair, immunity, and normal maintenance. In tumors, the same system gets hijacked.
This review walks through how EVs can reshape the tumor microenvironment - the local ecosystem around a cancer. They can influence fibroblasts, endothelial cells, and immune cells, nudging them toward behaviors that help the tumor survive.[1] That includes dampening anti-tumor immunity, supporting blood vessel growth, and rewiring metabolism under stress.
And yes, because biology enjoys making simple ideas annoying, EVs are heterogeneous. Different cells release different vesicles. The cargo changes with stress, nutrient levels, therapy exposure, and cell state. So when someone says "tumor EVs do X," the correct response is often, "Which ones, from where, under what conditions?" Science is fun that way if your idea of fun includes troubleshooting a network where every cable changes color under pressure.
The sketchy neighborhood around a tumor
One of the most interesting parts of this field is how EVs help turn the tumor microenvironment into a friendlier place for cancer and a worse one for immune cells. Reviews in recent years have highlighted EV roles in immune suppression, angiogenesis, invasion, and treatment resistance across many solid tumors.[2,3]
For example, EVs can carry immune-regulatory molecules that blunt T-cell activity or recruit cells that suppress anti-cancer responses.[2] If your immune system is the security team, EVs can act like fake badge credentials that keep getting the guards rerouted to the parking lot. Other vesicles help remodel extracellular matrix or condition distant tissues to receive metastatic cells.[3] That is one reason people talk about "pre-metastatic niches" - a phrase that sounds like real estate marketing for chaos.
The review also emphasizes that EV production is not just a constant leak from cells. It is tied to intracellular trafficking, lipid metabolism, and stress responses.[1] In other words, vesicle release is regulated. Tumor cells under therapeutic or metabolic pressure may actively alter EV output and cargo. That makes EVs less like random debris and more like adaptive system responses.
Why people are excited - and why the brakes are still on
If EVs naturally move cargo between cells, researchers understandably looked at them and thought: can we use that delivery system ourselves?
That idea has real appeal. Engineered EVs might carry drugs, RNA therapeutics, or immune-modulating payloads with better biocompatibility than some synthetic nanoparticles.[1] Recent reviews describe efforts to modify EV surfaces for targeting, load them with therapeutic cargo, or combine them with other delivery platforms.[4,5] In principle, you get a delivery vehicle that already knows how to circulate in biological terrain that would make most engineered systems file a complaint.
EVs are also being explored as biomarkers. Because they circulate in blood and other body fluids, they might help with liquid biopsy - sampling tumor signals without needing a chunk of tissue from somewhere your oncologist would rather not excavate.[1,3]
But this is where the review is refreshingly sober. The same features that make EVs exciting also make them difficult. Isolation methods vary. Cargo is inconsistent. Different labs may enrich different vesicle populations and then act surprised when the results do not line up. Manufacturing at scale is hard. Mechanisms remain incomplete. Regulatory standards are still catching up.[1]
That balance is useful. Cancer biology does not need more hype with a glossy finish. It needs fewer black boxes and more reproducible plumbing diagrams.
The real promise here
The big value of this review is that it frames EVs as part of tumor ecology, not just a trendy molecule shuttle. That systems view matters. Tumors survive by coordinating many small advantages at once - immune evasion, metabolic adaptation, stress tolerance, invasion. EVs may help connect those subsystems.[1]
If researchers can sort out which EV signals matter most, when they matter, and in which tumor settings, the payoff could be substantial. Better biomarkers. Better drug delivery. Maybe even better ways to interrupt the tumor's communications backbone rather than just swatting at one downstream effect at a time.
That would be useful, because cancer is annoyingly good at rerouting around single points of failure. Anyone who has debugged a distributed system already knows the feeling.
References
-
Cai W, Chen Y, Dai S, Cheng CS, Chen L. Extracellular vesicles in solid tumors: from tumor ecology to engineered therapeutics. Mol Cancer. 2026;25:26. doi:10.1186/s12943-026-02705-7. PubMed: 42321851
-
Sun Z, Wang L, Dong L, Wang X. Extracellular vesicles in the development of the tumor microenvironment and immunotherapy of hepatocellular carcinoma. J Hematol Oncol. 2022;15(1):149. doi:10.1186/s13045-022-01349-2. PMCID: PMC9627977
-
Xie F, Zhou X, Fang M, et al. Extracellular vesicles in cancer immune microenvironment and cancer immunotherapy. Adv Sci (Weinh). 2024;11(4):e2300430. doi:10.1002/advs.202300430. PMCID: PMC10851232
-
Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021;16(7):748-759. doi:10.1038/s41565-021-00931-2
-
Wiklander OPB, Brennan MÁ, Lötvall J, Breakefield XO, El Andaloussi S. Advances in therapeutic applications of extracellular vesicles. Sci Transl Med. 2019;11(492):eaav8521. doi:10.1126/scitranslmed.aav8521
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.